FDA Approves First Drug for Rare, Deadly Clotting Disorder

Adzynma is the first treatment to become available for patients with congenital thrombotic thrombocytopenic purpura.
Medscape Medical News

source https://www.medscape.com/viewarticle/998321?src=rss